Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...
To the Editor: Solomon et al. (Sept. 22 issue) 1 report on the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial, which showed ...
Women who experience menopause at an earlier age and have a reduction in cardiac function are at increased risk for adverse ...
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to treat patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, 1 ...
Hosted on MSN
Kerendia Approved for Heart Failure With Left Ventricular Ejection Fraction ≥40 Percent
MONDAY, July 14, 2025 (HealthDay News) -- Following priority review, the U.S. Food and Drug Administration approved Kerendia (finerenone) for the treatment of patients with heart failure with left ...
Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of ...
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback